Relvar Ellipta is a once-daily dual combination treatment comprising fluticasone furoate, an inhaled corticosteroid and vilanterol, a long-acting beta2-agonist, in a single inhaler, the Ellipta.
Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta ... in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says its results support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback